Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
ImmusanT announced today that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief...
ImmusanT today announced that it has initiated a clinical research study to explore the immunologic relationship between celiac disease and Type 1...
In autoimmune disorders such as celiac disease and Type 1 diabetes, the body's immune system attacks its own cells. Current treatments for many...
ImmusanT, Inc. announced today that it has relocated its operations to One Kendall Square, a 676,000-square-foot, mixed-use campus in the heart of...
ImmusanT announced today that Patrick H. Griffin, MD, has joined the biopharmaceutical company as Chief Medical Officer and Senior Vice President of...
ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the...
ImmusanT, Inc., a biotechnology company developing an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease,...
Biotechnology company ImmusanT, Inc. today announced it has established its operations in Cambridge, Massachusetts and is advancing its strategy to...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.